1.
Int J STD AIDS
; 21(11): 783-5, 2010 Nov.
Article
in English
| MEDLINE
| ID: mdl-21187364
ABSTRACT
Raltegravir (RAL), an HIV integrase inhibitor, may uncommonly induce an increase of serum creatine kinase (CK) both in naïve and antiretroviral (ARV)-experienced HIV-positive patients. We report the case of severe rhabdomyolysis requiring hospitalization in an ARV-experienced HIV/hepatitis C co-infected patient treated with a RAL-containing drug regimen. Factors favouring a severe clinical occurrence of RAL-induced rhabdomyolysis from cases reported in literature are described.
Subject(s)
HIV Integrase Inhibitors/adverse effects , Pyrrolidinones/adverse effects , Rhabdomyolysis/chemically induced , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Creatine Kinase/blood , Female , HIV Infections/blood , HIV Infections/drug therapy , HIV Integrase Inhibitors/therapeutic use , Humans , L-Lactate Dehydrogenase/blood , Middle Aged , Pyrrolidinones/therapeutic use , Raltegravir Potassium , Rhabdomyolysis/blood , Rhabdomyolysis/diagnosis
2.
3.
Acta Neurol (Napoli)
; 29(1): 38-57, 1974.
Article
in Italian
| MEDLINE
| ID: mdl-4208109
